ALS 4
Alternative Names: ALS-4Latest Information Update: 06 Jun 2024
At a glance
- Originator The Chinese University of Hong Kong
- Developer Aptorum Group
- Class Antibacterials; Small molecules
- Mechanism of Action Bacterial virulence inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Most Recent Events
- 05 Jun 2024 ALS 4 is still in phase I trials for Methicillin resistant staphylococcus aureus infections and Staphylococcus infections in Canada (PO)
- 05 Jun 2024 Aptorum Group has patent protection for ALS 4 in Japan
- 28 Apr 2024 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in Canada (PO)